This poster was presented at the British Thoracic Oncology Group conference, 2025. It aims to elicit expert clinical judgements on important factors for treatment decisions in advanced ALK-positive NSCLC, clinical monitoring requirements for treatment, perceived toxicity of ALK-TKIs, best practices in shared decision-making and key clinical priorities.
CORRELATE-UK Interim analysis: reported consistency of response to rimegepant in acute treatment of migraine in the first four attacks of a prospective real-world study
Nakajima K, O’Neil G, Abraham L, Johnston MC, Kilpatrick S, Cheong C, Fellows A, Petitjean C, Llewellyn S, Randall M, Walker R, Lambru G
(MTIS, 2026)


Copy Link